Patent ID: 9062105
Filing Date: 2015-06-23
Classification: A61F,A61K,A61N,C07K,C12Q

Abstract:
1. A method of treating or reducing the risk of retinopathy in a human, the method comprising administering to said human an anti-VEGF-A ligand that specifically binds to a human VEGF-A that is expressed by a VEGF-A nucleotide sequence comprising a SNP selected from the group consisting of: rs699947; rs833061; rs2010963; rs3025039; rs699946; rs2146323; rs1413711; rs833068; rs833069; rs3025000 and rs1570360; wherein the ligand comprises a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of: an Asp corresponding to position 204 of SEQ ID NO: 42 and a Leu corresponding to position 206 of SEQ ID NO: 42; and wherein said human comprises (i) an IGHG1*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid and (ii) a VEGF-A nucleotide sequence comprising said selected SNP.